Published on: 2026-05-13
Source: People’s Republic of China in Russian –
An important disclaimer is at the bottom of this article.
Recently, the State Administration for Market Regulation of China announced the approval of the registration application for the innovative product – the “Implantable Brain-Computer Interface System for Restoring Hand Movements” (NEO) by BrainCo Medical Technology (Shanghai) Co., Ltd., marking the world’s first release of a medical device with a “brain-computer” interface to the market. This landmark “global first certificate” was issued in the Pudong district of Shanghai.
The “brain-computer” interface is one of the key industries of the future, to which China pays special attention during the 15th five-year plan period. In the Pudong area, the development of innovative products in the categories “First-in-Class” (world’s first), “First-in-China” (China’s first), and “First-in-Human” (first applied to humans) continues, which accelerates the creation of a world-class biomedicine industry cluster.
Five years ago, as a result of a car accident, a young man named Dun from Henan Province suffered paralysis of the lower limbs with spinal cord injury. In November 2024, at Huashan Hospital of Fudan University, a device the size of a coin — the very approved BrainCo brain-computer interface system — was implanted into his head. This was the first brain-computer interface implantation surgery in Shanghai.
A week after the operation, the man was discharged from the hospital and continued rehabilitation at home. During training, the brain-computer interface precisely decoded the recorded electroencephalographic signals, first “understanding” the man’s intentions, and then converting them into commands to operate a pneumatic glove. Soon, the young man named Dun was able to control the pneumatic glove with the power of his thoughts to grasp wooden blocks. After six months, he was already able to independently lift a glass of water.As rehabilitation continued, a year later, new changes occurred: without the help of the “brain-computer” interface device, interacting with both hands, he was able to write the word “thank you.”
“This is a qualitative leap, which means that the patient, in addition to the restoration of motor function of the hands with the help of an external device, has also undergone significant neurological recovery,” stated Mao Yin, director of Huashan Hospital at Fudan University.
As a leading center of the Chinese biopharmaceutical industry, the Pudong district has already gathered about 10 companies in the field of “brain-computer” interfaces and related neurotechnologies, covering all the main technological directions.
The action plan for the development of the future “brain-computer” interface industry in Shanghai (2025–2030) sets the goal: by 2030, Shanghai will achieve high-quality control over the brain, products with a “brain-computer” interface will be widely applied in clinical practice, and Shanghai will become a global center of innovation in this field.
According to data from the Shanghai Commission for Science and Technology of the Pudong district, as one of the regions in China with the most complete biopharmaceutical industry chain, the best ecosystem, the largest concentration of talent, the most active innovations, and the most effective scientific research activities, Pudong district concentrates more than 4,000 enterprises related to biopharmaceuticals. The production volume in this industry in 2025 reached 449.4 billion yuan, accounting for 43% of the total volume throughout Shanghai (the share increased compared to the previous year).
The internationalization of Pudong’s biopharmaceutical industry has also significantly accelerated. In 2025, 42 deals for technology licensing and business cooperation with foreign partners were signed in the Pudong area, totaling 25.5 billion US dollars, which indicates deep integration into the global network of biopharmaceutical innovation and commercialization.
Please note; This information is raw content obtained directly from the information source. It represents an accurate report of what the source claims and does not necessarily reflect the position of MIL-OSI or its clients.